Stock events for Monte Rosa Therapeutics, Inc. (GLUE)
In January 2026, GLUE stock reached a 52-week high and raised approximately $345 million gross through a follow-on equity offering. In March 2026, the company reported its Q4 and full-year 2025 financial results, which missed consensus estimates, but highlighted positive pipeline milestones. In April 2026, the Chief Business & Legal Officer sold 5,845 shares of common stock.
Demand Seasonality affecting Monte Rosa Therapeutics, Inc.’s stock price
Monte Rosa Therapeutics, as a clinical-stage biotechnology company, does not experience typical demand seasonality. Demand for its product candidates is driven by clinical trial progression, regulatory approvals, and medical need, rather than seasonal consumer purchasing patterns.
Overview of Monte Rosa Therapeutics, Inc.’s business
Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biotechnology company focused on developing innovative small molecule precision medicines using molecular glue degraders (MGDs). Their pipeline includes MRT-2359 for MYC-driven tumors, MRT-6160 for autoimmune and inflammatory diseases (partnered with Novartis), MRT-8102 for inflammatory diseases, and CDK2/Cyclin E1-directed MGDs for various cancers. The company utilizes its QuEEN discovery engine and has collaborations with Roche and Novartis.
GLUE’s Geographic footprint
Monte Rosa Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States, and operates within the United States market.
GLUE Corporate Image Assessment
Monte Rosa Therapeutics' brand reputation has been positively influenced by positive interim Phase 1 data for MRT-8102, the 100% PSA response rate observed with MRT-2359, strategic collaborations with Novartis and Roche, and its QuEEN discovery engine. Events affecting reputation include a significant miss on Q4 2025 revenue, shareholder dilution, and insider selling activity. The company has a "Moderate Buy" consensus rating from analysts.
Ownership
Monte Rosa Therapeutics has substantial institutional ownership, with 165 institutional owners holding approximately 79.96% of the stock. Major institutional owners include NEA Management Company, LLC, Price T Rowe Associates Inc, TCG Crossover Management, LLC, Versant Venture Management, LLC, Baker Bros. Advisors Lp, BlackRock, Inc., Bvf Inc/il, Suvretta Capital Management, Llc, Vanguard Group Inc, State Street Corp, New Enterprise Associates, Inc., and Dimension Capital I, L.P. Individual insiders hold approximately 0.593% of the shares and have sold more shares than they have bought in the past three months.
Ask Our Expert AI Analyst
Price Chart
$18.32
